Predicting Immunotherapy Efficacy in Head and Neck Squamous Cell Cancer

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

NCT04858269 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy

NCT01256385 ·Status: COMPLETED ·Phase: PHASE2

Ipilimumab for Head and Neck Cancer Patients

NCT02812524 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT05359692 ·Status: WITHDRAWN ·Phase: PHASE2

Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery

NCT03565783 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy

NCT01358097 ·Status: COMPLETED

Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma

NCT05328024 ·Status: RECRUITING

89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC

NCT05423197 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

NCT03422536 ·Status: COMPLETED ·Phase: PHASE2

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)

NCT04938609 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Efficacy and Safety of Immunotherapy Combined With Neoadjuvant Chemotherapy in Patients With Locally Advanced HPV (-) Head and Neck Squamous Cell Carcinoma: a Phase II Clinical Trial

NCT04929067 ·Status: UNKNOWN ·Phase: PHASE2

Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck

NCT02769520 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Prognostic Immune Biomarkers in HNSCC

NCT05941676 ·Status: COMPLETED

Safety and Efficacy of APG-157 in Head and Neck Cancer

NCT05312710 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

NCT05726370 ·Status: RECRUITING ·Phase: PHASE2

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

NCT07281417 ·Status: RECRUITING ·Phase: PHASE2

TumorGraft- Guided Therapy for Improved Outcomes in Head and Neck Squamous Cell Cancer- A Feasibility Study

NCT02752932 ·Status: COMPLETED ·Phase: NA

Study of Chemo-Immunotherapy in Head and Neck Cancer Patients

NCT01149902 ·Status: UNKNOWN ·Phase: PHASE1

Effectiveness and Safety of Nivolumab in Participants That Have Head and Neck Cancer That Has Come Back or Has Spread

NCT03569436 ·Status: COMPLETED

Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy

NCT05283226 ·Status: RECRUITING ·Phase: PHASE2

Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC

NCT05053737 ·Status: COMPLETED ·Phase: PHASE1

Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site

NCT05110781 ·Status: TERMINATED ·Phase: PHASE2

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer

NCT06223568 ·Status: RECRUITING ·Phase: PHASE2

Pembrolizumab in HNSCC With Residual Disease After Radiation

NCT02892201 ·Status: TERMINATED ·Phase: PHASE2

Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC

NCT04470024 ·Status: RECRUITING ·Phase: PHASE1